• Maximum tolerated dose of docetaxel and oxaliplatin [ Designated as safety issue: Yes ]
• Toxicity [ Designated as safety issue: Yes ]

• Maximum tolerated dose of docetaxel and oxaliplatin
• Toxicity

• Tolerance profile [ Designated as safety issue: Yes ]
• Recommended phase III dose [ Designated as safety issue: No ]
• Efficacy [ Designated as safety issue: No ]
• Complete pathological response [ Designated as safety issue: No ]
• Duration of the objective response [ Designated as safety issue: No ]
• Time to progression [ Designated as safety issue: No ]

• Tolerance profile
• Recommended phase III dose
• Efficacy
• Complete pathological response
• Duration of the objective response
• Time to progression

RATIONALE: Drugs used in chemotherapy, such as docetaxel and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of docetaxel and oxaliplatin and to see how well they work in treating patients with stage III or stage IV ovarian epithelial cancer.

OBJECTIVES:

Primary

• Determine the maximum tolerated dose of docetaxel and oxaliplatin in patients with stage III or IV ovarian epithelial cancer.
• Determine the toxicity of this regimen in these patients.

Secondary

• Determine the tolerance profile of patients treated with this regimen.
• Determine a recommended phase III dose of this regimen in these patients.
• Determine the efficacy of this regimen, in terms of objective response rate and radiological and biological response rate (CA 125), in these patients.
• Determine the complete pathological response in patients treated with this regimen as first-line therapy.
• Determine the duration of the objective response in patients treated with this regimen.
• Determine the time to progression in patients treated with this regimen.

OUTLINE: This is a dose-escalation, multicenter study.

Patients receive docetaxel IV over 1 hour and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed monthly for 3 months.

PROJECTED ACCRUAL: A total of 30-39 patients will be accrued for this study.

• Drug: docetaxel
• Drug: oxaliplatin

DISEASE CHARACTERISTICS:

• Histologically confirmed ovarian epithelial cancer

  • Stage III or IV disease
  • Metastatic peritoneal, lymphatic, or visceral disease
• Measurable or evaluable disease
• Previously untreated disease OR relapsed disease more than 6 months after the completion of a platinum-containing chemotherapy regimen
• No symptomatic brain metastases

PATIENT CHARACTERISTICS:

Age

• 18 to 75

Performance status

• WHO 0-2 (0 in patients 70 to 75 years of age)

Life expectancy

• Not specified

Hematopoietic

• Absolute neutrophil count at least 1,500/mm^3
• Platelet count at least 100,000/mm^3

Hepatic

• Bilirubin no greater than 1.25 times upper limit of normal (ULN)
• AST and ALT no greater than 3 times ULN
• Alkaline phosphatase less than 2.5 times ULN

Renal

• Creatinine no greater than 1.4 mg/dL

Other

• No serious uncontrolled infection
• No intolerance to polysorbate 80
• No peripheral neuropathy greater than grade 1
• No neurological or mental disease that would preclude study participation
• No other prior malignancy except curatively treated basal cell skin cancer or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• See Disease Characteristics
• More than 4 weeks since prior chemotherapy
• No more than 1 prior chemotherapy regimen
• No prior oxaliplatin or docetaxel

Endocrine therapy

• Not specified

Radiotherapy

• More than 4 weeks since prior radiotherapy

Surgery

• Not specified

Other

• More than 28 days since prior participation in another clinical study
• No other concurrent anticancer treatment